NCT06335069View on ClinicalTrials.gov

18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer.

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Breast CancerBreast NeoplasmsBreast Diseases
Interventions
DIAGNOSTIC_TEST

68Ga-FAPI-46 PET/CT and 68Ga-FAPI-46 PET/MRI

All participating patients will undergo an additional 68Ga-FAPI- 46 PET/CT and 68Ga-FAPI-46 PET/MRI scan prior to their breast cancer treatment.

Trial Locations (1)

5800

RECRUITING

Maastricht University Medical Center+, Maastricht

All Listed Sponsors
lead

Maastricht University Medical Center

OTHER

NCT06335069 - 18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer. | Biotech Hunter | Biotech Hunter